Selective serotonin-reuptake inhibitors in the treatment of panic disorder: a systematic review of placebo-controlled studies

References

• American Psychiatric Association. Practice Guideline for Treatment of Patients With Panic Disorder (Second Edition). American Psychiatric Publishing Inc., VA, USA (2009).
   Google Scholar
• Kasper S, Resinger E. Panic disorder: the place of benzodiazepines and selective serotonin reuptake inhibitors. Eur. Neuropsichopharmacol.11, 307–321 (2001).
   PubMed Web of Science ®Google Scholar
• Garakani H, Zitrin CM, Klein DF. Treatment of panic disorder with imipramine alone. Am. J. Psychiatry141(3), 446–448 (1984).
   Google Scholar
• Mavissakalian M, Perel JM, Michelson L. The relationship of plasma imipramine and N-desmethylimipramine to improvement in agoraphobia. J. Clin. Psychopharmacol.4(1), 36–40 (1984).
   PubMed Web of Science ®Google Scholar
• Zitrin CM. Differential treatment of phobias: use of imipramine for panic attacks. J. Behav. Ther. Exp. Psychiatry14(1), 11–18 (1983).
   PubMed Web of Science ®Google Scholar
• Cassano GB, Petracca A, Perugi G et al. Clomipraminee for panic disorder: I. The first 10 weeks of a long-term comparison with imipramine. J. Affect. Disord.14(2), 123–127 (1988).
   Google Scholar
• Lydiard RB, Morton WA, Emmanuel NP et al. Preliminary report: placebo-controlled, double-blind study of the clinical and metabolic effects of desipramine in panic disorder. Psychopharmacol. Bull.29(2), 183–188 (1993).
   PubMedGoogle Scholar
• Nardi AE, Nascimento I, Valença AM et al. Respiratory panic disorder subtype: acute and long-term response to nortriptyline, a noradrenergic tricyclic antidepressant. Psychiatry Res.120(3), 283–293 (2003).
   Google Scholar
• The American Psychiatric Publishing Textbook of Psychiatry (5th Edition). Hales RH, Yudofsky SC, Gabbard GN (Eds). American Psychiatric Publishing Inc., VA, USA (2008).
   Google Scholar
• Zohar J, Westenberg HG. Anxiety disorders: a review of tricyclics antidepressants and selective serotonin reuptake inhibitors. Acta Psychiatry Scand. Supl.403, 39–49 (2000).
   PubMedGoogle Scholar
• Coplan JD, Pine DS, Papp LA, Gorman JM. An algorithm-oriented treatment approach for panic disorder. Psychiatr. Ann.26, 192–201 (1996).
   Google Scholar
• Pollack MH, Smoller JW. Pharmacologic approaches to treatment-resistant panic disorder. In: Challenges in Clinical Practice: Pharmacologic and Psychosocial Strategies. Pollack MH, Otto MW, Rosenbaum JF (Eds). Guilford Press, NY, USA, 89–112 (1996).
   Google Scholar
• Stahl SM. Mechanism of action of serotonin selective reuptake inhibitors: serotonin receptors and pathways mediate therapeutic effects and side effects. J. Affect. Disord.51, 215–235 (1998).
   PubMed Web of Science ®Google Scholar
• Maron E, Shlik J. Serotonin function in panic disorder: important, but why? Neuropsychopharmacology31, 1–11 (2006).
   PubMed Web of Science ®Google Scholar
• Kennett GA, Lightowler S, de Biasi V et al. Effect of chronic administration of selective 5-hydroxytryptamine and noradrenaline uptake inhibitors on a putative index of 5-HT2C/2B receptor function. Neuropharmacology33(12), 1581–1588 (1994).
   PubMedGoogle Scholar
• Yamauchi M, Tatebayashi T, Nagase K, Kojima M, Imanishi T. Chronic treatment with fluvoxamine desensitizes 5-HT2C receptor-mediated hypolocomotion in rats. Pharmacol. Biochem. Behav.78(4), 683–689 (2004).
   Google Scholar
• Goddard AW, Sholomskas DE, Walton KE et al. Effects of tryptophan depletion in panic disorder. Biol. Psychiatry36, 775–777 (1994).
   PubMed Web of Science ®Google Scholar
• Kent JM, Coplan JD, Martinez J, Karmally W, Papp LA, Gorman JM. Ventilatory effects of tryptophan depletion in panic disorder: a preliminary report. Psychiatry Res.64, 83–90 (1996).
   PubMed Web of Science ®Google Scholar
• Gorman JM, Kent JM, Sullivan GM, Coplan JM. Neuroanatomical hypothesis of panic disorder, revised. Am J. Psychiatry157(4), 493–505 (2000).
   PubMed Web of Science ®Google Scholar
• Maron E, Kuikka JT, Shlik J, Vasar V, Vanninen E, Tiihonen J. Reduced brain serotonin transporter binding in patients with panic disorder. Psychiatry Res.132, 173–181 (2004).
   PubMed Web of Science ®Google Scholar
• Inoue T, Li XB, Abekawa T et al. Selective serotonin reuptake inhibitor reduces conditioned fear through its effect in the amygdale. Eur. J. Pharmacol.497, 311–316 (2004).
   Google Scholar
• Michelson D, Lydiard RB, Pollack MH et al. Outcome assessment and clinical improvement in panic disorder: evidence from a randomized controlled trial of fluoxetine and placebo. Am J. Psychiatry155, 1570–1577 (1998).
   PubMed Web of Science ®Google Scholar
• Londborg PD, Wolkow R, Smith WT et al. Sertraline in the treatment of panic disorder: a multi-site, double-blind, placebo-controlled, fixed-dose investigation. Br. J. Psychiatry173(7), 54–60 (1998).
   PubMed Web of Science ®Google Scholar
• Pollack, MH, Otto MW, Worthington JJ, Manfro GG, Wolkow R. Sertraline in the treatment of panic disorder: a flexible-dose multicenter trial. Arch. Gen. Psychiatry55, 1010–1016 (1998).
   PubMed Web of Science ®Google Scholar
• Pohl RB, Wolkow RM, Clary CM. Sertraline in the treatment of panic disorder: a double-blind multicenter trial. Am J. Psychiatry155, 1189–1195 (1998).
   PubMed Web of Science ®Google Scholar
• Ballenger JC, Wheadon DE, Steiner M, Bushnell W, Gergel IP. Double-blind, fixed-dose, placebo-controlled study of paroxetine in the treatment of panic disorder. Am J. Psychiatry155, 36–42 (1998).
   PubMed Web of Science ®Google Scholar
• Lecrubier Y, Bakker A, Dunbar G, Judge R; the Collaborative Paroxetine Panic Study Investigators. A comparison of paroxetine, clomipramine and placebo in the treatment of panic disorder. Acta Psychiatr. Scand.95, 145–152 (1997).
   PubMed Web of Science ®Google Scholar
• Pollack M, Mangano R, Entsuah R, Tzanis E, Simon NM. A randomized controlled trial of venlafaxine ER and paroxetine in the treatment of outpatients with panic disorder. Psychopharmacology194, 233–242 (2007).
   PubMed Web of Science ®Google Scholar
• Sheehan DV, Burnham DB, Iyengar MK, Perera P. Efficacy and tolerability of controlled-release paroxetine in the treatment of panic disorder. J. Clin. Psychiatry66, 34–40 (2005).
   PubMed Web of Science ®Google Scholar
• Stahl SM, Gergel I, Li D. Escitalopram in the treatment of panic disorder: a double-blind, randomized, placebo-controlled trial. J. Clin. Psychiatry64, 1322–1327 (2003).
   PubMed Web of Science ®Google Scholar
• Nair NPV, Bakish D, Saxena B, Amin M, Schwartz G, West TEG. Comparison of luvoxamine, imipramine and placebo in the treatment of outpatients with panic disorder. Anxiety2, 192–198 (1996).
   PubMedGoogle Scholar
• Asnis GM, Hameedia FA, Goddardb AW et al. Fluvoxamine in the treatment of panic disorder: a multi-center, double-blind, placebo-controlled study in outpatients. Psychiatry Res.103, 1–14 (2001).
   PubMed Web of Science ®Google Scholar
• Smit F, Willemse G, Meulenbeek P et al. Preventing panic disorder: cost-effectiveness analysis alongside a pragmatic randomised trial. Cost Eff. Resour. Alloc.7, 8 (2009).
   Google Scholar
• Sheehan DV, Harnett-Sheehan K. The role of SSRIs in panic disorder. J. Clin. Psychiatry57(Suppl.) 10, 51–58; discussion 59–60 (1996).
   PubMedGoogle Scholar
• Hirschfeld RM. Placebo response in the treatment of panic disorder. Bull. Menninger Clin.60(2 Suppl. A), A76–A86 (1996).
   Google Scholar
• Huppert JD, Schultz LT, Foa EB et al. Differential response to placebo among patients with social phobia, panic disorder, and obsessive-compulsive disorder. Am. J. Psychiatry161, 1485–1487 (2004).
   PubMed Web of Science ®Google Scholar
• Piercy MA, Sramek JJ, Kurtz NM, Cutler NR. Placebo response in anxiety disorders. Ann. Pharmacother.30(9), 1013–1019 (1996).
   PubMed Web of Science ®Google Scholar
• Dannon PN, Iancu I, Cohen A, Lowengrub K, Grunhaus L, Kotler M. Three year naturalistic outcome study of panic disorder patients treated with paroxetine. BMC Psychiatry11(4), 16 (2004).
   Google Scholar
• Dannon PN, Iancu I, Lowengrub K et al. A naturalistic long-term comparison study of selective serotonin reuptake inhibitors in the treatment of panic disorder. Clin. Neuropharmacol.30(6), 326–334 (2007).
   PubMed Web of Science ®Google Scholar
• Toni C, Perugi G, Frare F et al. A prospective naturalistic study of 326 panic-agoraphobic patients treated with antidepressants. Pharmacopsychiatry33(4), 121–131 (2000).
   PubMed Web of Science ®Google Scholar
• Kinzl JF. Major depressive disorder, antidepressants and sexual dysfunction. Neuropsychiatry23(2), 134–138 (2009).
   Google Scholar
• Rosenbaum JF, Pollack MH, Pollock RA. Clinical issues in the long-term treatment of panic disorder. J. Clin. Psychiatry57(Suppl. 10), 44–48; discussion 49–50 (1996).
   Google Scholar
• Kilbane EJ, Gokbayrak NS, Galynker I, Cohen L, Tross S. A review of panic and suicide in bipolar disorder: does comorbidity increase risk? Affect. Disord.115(1–2), 1–10 (2009).
   PubMed Web of Science ®Google Scholar
• Nardi AE, Freire RC, Zin WA. Panic disorder and control of breathing. Respir. Physiol. Neurobiol.167(1), 133–143 (2009).
   PubMed Web of Science ®Google Scholar
• Gorman JM, Fyer MR, Goetz R et al. Ventilatory physiology of patients with panic disorder. Arch. Gen. Psychiatry45, 31–39 (1988).
   PubMed Web of Science ®Google Scholar
• Griez E, Zandbergen J, Pols H, de Loof C. Response to 35% CO2 as a marker of panic in severe anxiety. Am. J. Psychiatry,147, 796–797 (1990).
   Google Scholar
• Klein E, Zohar J, Geraci MF, Murphy DL, Uhde TW. Anxiogenic effects of m-CPP in patients with panic disorder: comparison to caffeine’s anxiogenic effects. Biol. Psychiatry30, 973–984 (1991).
   PubMed Web of Science ®Google Scholar
• Nardi AE, Lopes FL, Freire RC et al. Panic disorder and social anxiety disorder subtypes in a caffeine challenge test. Psychiatry Res.169(2), 149–153 (2009).
   PubMed Web of Science ®Google Scholar
• Freire RC, De Carvalho MR, Joffily M, Zin WA, Nardi AE. Anxiogenic properties of a computer simulation for panic disorder with agoraphobia. J. Affect. Disord. DOI: 10.1016/j.jad.2009.12.031 (2010) (Epub ahead of print).
   Google Scholar
• Smoller JW, Pollack MH, Otto MW, Rosenbaum JF, Kradin RL. Panic anxiety, dyspnea, and respiratory disease. Theoretical and clinical considerations. Am. J. Respir. Crit. Care Med.154(1), 6–17 (1996).
   PubMed Web of Science ®Google Scholar
• Miller HE, Deakin JF, Anderson IM. Effect of acute tryptophan depletion on CO2-induced anxiety in patients with panic disorder and normal volunteers. Br. J. Psychiatry176, 182–188 (2000).
   PubMed Web of Science ®Google Scholar
• Bertani A, Perna G, Arancio C, Caldirola D, Bellodi L. Pharmacologic effect of imipramine, paroxetine, and sertraline on 35% carbon dioxide hypersensitivity in panic patients: a double-blind, random, placebo-controlled study. J. Clin. Psychopharmacol.17, 97–101 (1997).
   PubMed Web of Science ®Google Scholar
• Perna G, Bertani A, Gabriele A, Politi E, Bellodi L. Modification of 35% carbon dioxide hypersensitivity across one week of treatment with clomipramine and fluvoxamine: a double-blind, randomized, placebo-controlled study. J. Clin. Psychopharmacol.17, 173–178 (1997).
   PubMed Web of Science ®Google Scholar
• Bell C, Forshall S, Adrover M et al. Does 5-HT restrain panic? A tryptophan depletion study in panic disorder patients recovered on paroxetine. J. Psychopharmacol.16, 5–14 (2002).
   PubMed Web of Science ®Google Scholar
• Schruers K, Griez E. The effects of tianeptine or paroxetine on 35% CO2 provoked panic in panic disorder. J. Psychopharmacol.18, 553–558 (2004).
   PubMed Web of Science ®Google Scholar
• Pollack MH, Simon NM, Worthington JJ et al. Combined paroxetine and clonazepam treatment strategies compared to paroxetine monotherapy for panic disorder. J. Psychopharmacol.17(3), 276–282 (2003).
   PubMed Web of Science ®Google Scholar
• Simon NM, Kaufman RE, Hoge EA et al. Open-label support for duloxetine for the treatment of panic disorder. CNS Neurosci. Ther.15(1), 19–23 (2009).
   PubMed Web of Science ®Google Scholar
• Sarchiapone M, Amore M, De Risio S et al. Mirtazapine in the treatment of panic disorder: an open-label trial. Int. Clin. Psychopharmacol.18(1), 35–38 (2003).
   PubMed Web of Science ®Google Scholar